Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response.
Katia B B PagnanoAna Beatriz P LopesEliana C MirandaMárcia T DelamainGislaine O DuarteBruna R V RodriguesValquiria M O PovoaGraziele C P FurlinJessica C ViannaMatheus A S da SilvaCarmino A De SouzaErich V De PaulaPublished in: American journal of hematology (2020)